Hence then, the article about novartis presents new five year data on disability outcomes and safety of kesimpta ofatumumab in people living with relapsing multiple sclerosis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis )
Last updated :
Also on site :
- APOD: 2026 September 23 – A New Lunar Crater: McGetchin
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- The Seemingly Harmless 4-Word ‘I’ Statement That’s Actually a Massive Relationship Red Flag, According to a Psychologist